269 related articles for article (PubMed ID: 34274891)
1. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
Guerrini R; Chiron C; Vandame D; Linley W; Toward T
Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis.
Wu J; Zhang L; Zhou X; Wang J; Zheng X; Hu H; Wu D
Front Pharmacol; 2022; 13():980937. PubMed ID: 36120377
[No Abstract] [Full Text] [Related]
4. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
[TBL] [Abstract][Full Text] [Related]
5. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
Zhang L; Li W; Wang C
Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
[TBL] [Abstract][Full Text] [Related]
7. Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications.
Lopez JC; Pare JR; Blackmer AB; Orth LE
J Pediatr Health Care; 2022; 36(5):479-488. PubMed ID: 35987555
[TBL] [Abstract][Full Text] [Related]
8. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
Schoonjans AS; Ceulemans B
Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486
[TBL] [Abstract][Full Text] [Related]
9. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysis.
Sharawat IK; Panda PK; Kasinathan A; Panda P; Dawman L; Joshi K
Seizure; 2021 Feb; 85():119-126. PubMed ID: 33461030
[TBL] [Abstract][Full Text] [Related]
11. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
[TBL] [Abstract][Full Text] [Related]
12. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
13. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
[TBL] [Abstract][Full Text] [Related]
14. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
[TBL] [Abstract][Full Text] [Related]
15. Stiripentol for the treatment of seizures associated with Dravet syndrome.
Chiron C
Expert Rev Neurother; 2019 Apr; 19(4):301-310. PubMed ID: 30900478
[TBL] [Abstract][Full Text] [Related]
16. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies.
Sullivan J; Simmons R
Drugs Today (Barc); 2021 Jul; 57(7):449-454. PubMed ID: 34268532
[TBL] [Abstract][Full Text] [Related]
17. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pharmacological treatments for Dravet syndrome: Systematic review and network meta-analysis.
Xia D; Zhang P; Chen Y; Liu X; Chen Y
Seizure; 2024 Apr; 117():90-97. PubMed ID: 38354598
[TBL] [Abstract][Full Text] [Related]
19. Fenfluramine (Fintepla) for Dravet syndrome.
Med Lett Drugs Ther; 2021 Aug; 63(1630):126-128. PubMed ID: 34550111
[No Abstract] [Full Text] [Related]
20. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]